A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms TRANSCEND-NHL-006
- Sponsors Juno Therapeutics
- 06 Nov 2019 Results of patients treated in the TRANSCEND, OUTREACH and PILOT studies released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 29 Jan 2019 Planned End Date changed from 2 May 2021 to 30 Dec 2021.
- 29 Jan 2019 Planned primary completion date changed from 2 May 2021 to 30 Dec 2021.